AIMS The HOMAGE randomised trial found that spironolactone reduced left atrial volume index (LAVI), E:A ratio, and a marker of collagen type I synthesis (PICP) in patients at risk of heart failure (HF). Previous trials showed that patients with HF, preserved ejection fraction and low serum collagen type I C-terminal telopeptide to matrix metalloproteinase-1 (CITP:MMP-1) ratio, associated with high collagen cross-linking, had less improvement in diastolic function with spironolactone. We evaluate...
AIMS Remote monitoring of pulmonary artery (PA) pressure has reduced heart failure (HF) hospitalizations in chronic HF as elevation of PA pressure provides information that can guide treatment. The venous system is characterized by high capacitance, thus substantial increases in intravascular volume can occur before filling pressures increase. The inferior vena cava (IVC) is a highly compliant venous conduit and thus a candidate for early detection of change in intravascular volume. We aimed to ...
#1R I S Alnuwaysir(UMCG: University Medical Center Groningen)H-Index: 1
#2N. Grote Beverborg(UMCG: University Medical Center Groningen)H-Index: 1
Last. P. van der Meer(UMCG: University Medical Center Groningen)H-Index: 6
view all 15 authors...
Aims null Whereas the combination of anaemia and chronic kidney disease (CKD) has been extensively studied in patients with heart failure (HF), the contribution of iron deficiency (ID) to this dysfunctional interplay is unknown; we aimed to assess clinical associates and pathophysiological pathways related to ID in this multimorbid syndrome. null Methods and results null We studied 2151 patients with HF from the BIOSTAT-CHF cohort. Patients were stratified based on ID (TSAT null null Conclusion ...
#2Richard N. Channick(UCLA: University of California, Los Angeles)H-Index: 46
Last. Irene M. Lang(Medical University of Vienna)H-Index: 45
view all 14 authors...
AIMS The number of pulmonary arterial hypertension (PAH) patients with comorbidities is increasing and there are limited data on response to PAH-targeted therapies in this population. These post hoc analyses explored the effect of selexipag in PAH patients with cardiovascular comorbidities in the GRIPHON study. METHODS AND RESULTS Randomized patients (n = 1156) were classified using three methods: (i) by subgroups defined according to previously published comorbidity count and restrictive haemod...
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies. To learn more, you can find in our Privacy Policy.